18:09 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Akcea's AKCEA-APO(a)-LRx reduces LPA levels in Phase II

Akcea Therapeutics Inc. (NASDAQ:AKCA) said AKCEA-APO(a)-LRx led to significant dose-dependent reductions in lipoprotein(a) (LPA) compared with placebo in a Phase II trial to reduce elevated LPA levels in patients with established cardiovascular disease. The company...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market for investors through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18...
23:28 , Jun 7, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

New Therapeutic Targets and Biomarkers: May 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May 2018. Therapeutic targets are defined as any protein, gene or other molecule...
22:43 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest AIBP could help treat neuropathic pain. In mouse models of lipopolysaccharide (LPS)- and chemical-induced neuropathic pain, intrathecal AIBP decreased mechanical allodynia compared with vehicle. Also in the model of chemical-induced neuropathic...
23:02 , May 31, 2018 |  BC Extra  |  Preclinical News

TLR4 inhibitor could help treat chemotherapy-induced pain

A Cell Reports study from researchers at University of California San Diego showed spinal injection of a toll-like receptor 4-binding protein reversed chemotherapy-induced neuropathic pain in mice. The findings suggest a new, non-opioid approach to...
19:24 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Akcea starts Phase IIb of AKCEA-APOCIII-LRx in hypertriglyceridemia

Akcea Therapeutics Inc. (NASDAQ:AKCA) began a double-blind, placebo-controlled Phase IIb trial to evaluate four doses of AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx) in 100 patients with hypertriglyceridemia and established cardiovascular disease (CVD). AKCEA-APOCIII-LRx is a ligand conjugated antisense version...
21:59 , Oct 13, 2017 |  BC Extra  |  Financial News

Shenzhen Hepalink triples stake in Resverlogix

Resverlogix Corp. (TSX:RVX) said Chinese API distributor Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) invested C$87 ($69.7 million) in a private placement through the issue of 60.4 million units at C$1.44. Each unit consists of a...
19:54 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

Madrigal completes enrollment in Phase II of MGL-3196 for HeFH

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) said it has enrolled 113 patients in a Phase II trial of MGL-3196 (VIA-3196) to treat heterozygous familial hypercholesterolemia (HeFH), exceeding its target enrollment of 105. The company said it would...
20:16 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

DSMB recommends fourth continuation of Phase III BETonMACE trial of apabetalone

Resverlogix Corp. (TSX:RVX) said an independent DSMB recommended for the fourth time continuation of the double-blind, placebo-controlled, international Phase III BETonMACE trial evaluating twice-daily 100 mg apabetalone (RVX000222, RVX-208) with high-dose statin therapy in patients...
21:06 , Apr 27, 2017 |  BC Week In Review  |  Clinical News

AKCEA-APO(a)-LRx: Ph IIb started

Ionis’ Akcea Therapeutics Inc. subsidiary began a double-blind, placebo-controlled, North American Phase IIb trial to evaluate 5 dose levels of subcutaneous AKCEA-APO(a)-LRx in about 270 patients with hyperlipoproteinemia(a) and established cardiovascular disease. In January, Ionis and...